CN107184565A - A kind of preparation method of ibuprofen sustained release capsules - Google Patents

A kind of preparation method of ibuprofen sustained release capsules Download PDF

Info

Publication number
CN107184565A
CN107184565A CN201710403211.3A CN201710403211A CN107184565A CN 107184565 A CN107184565 A CN 107184565A CN 201710403211 A CN201710403211 A CN 201710403211A CN 107184565 A CN107184565 A CN 107184565A
Authority
CN
China
Prior art keywords
brufen
preparation
sba
particle
mesoporous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710403211.3A
Other languages
Chinese (zh)
Other versions
CN107184565B (en
Inventor
赖木水
赖海杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Music Spring Pharmaceutical Co Ltd
Original Assignee
Hainan Music Spring Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hainan Music Spring Pharmaceutical Co Ltd filed Critical Hainan Music Spring Pharmaceutical Co Ltd
Priority to CN201710403211.3A priority Critical patent/CN107184565B/en
Publication of CN107184565A publication Critical patent/CN107184565A/en
Application granted granted Critical
Publication of CN107184565B publication Critical patent/CN107184565B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the preparation method of ibuprofen sustained release capsules, belong to field of pharmaceutical preparations.It comprises the following steps:1) mesoporous material and polyethylene glycol are added and ultrasound is carried out in solvent;2) brufen is added into dicyandiamide solution, stirring solvent flashing obtains the mesoporous particles of load brufen;Mesoporous particles are coated using organic polymer auxiliary material, the particle of acquisition pulverizes and sieves, encapsulated to produce.

Description

A kind of preparation method of ibuprofen sustained release capsules
Technical field
The present invention relates to the preparation method of ibuprofen sustained release capsules, belong to field of pharmaceutical preparations.
Background technology
Brufen (brufen, ibuprofen) is a kind of NSAIDs (NSAIDS), with analgesia, anti-inflammatory, Antirheumatic, antipyretic effect, it is slight to moderate pain such as arthralgia, courbature, neuralgia, headache, antimigraine, tooth for alleviating Bitterly, dysmenorrhoea etc., is also used for generating heat caused by common cold or influenza.
Although having used more than 40 years in the mankind, brufen is considered as safe, as NSAIDs, It still can cause numerous adverse reactions, including:1) digestive tract damage, with gastrointestinal reaction such as Nausea and vomiting, stomachache, stomach Burn feeling and slight indigestion are the most common, and severe patient may occur in which gastric and duodenal ulcer, rotten to the corn and gastric perforation and go out Blood;2) renal damage, be mainly shown as acute renal insufficiency, interstitial nephritis, town dolorosa nephritis, necrosis of renal papillae, albuminuria, Nephrotic syndrome or renal failure etc.;3) hepatic lesion, almost all of NSAIDS results in hepatic lesion, shows as liver enzyme liter Height, severe patient necrosis of liver cells;4) cutaneous anaphylaxis, such as fash, nettle rash, itch, exfoliative dermatitis, bullous skin disease Etc. cutaneous anaphylaxis;5) hematopoietic disorders, such as anaemia, leukopenia, thrombopenia, pancytopenia, grain Granulocytopenia etc.;And 6) neurological symptom, such as headache, drowsiness, dizzy, tinnitus.Wherein with gastrointestinal side effect To be most common, it was reported that gastrointestinal side effect occurs in about 15%-30% long-term prescription person, or even there is digestibility and burst Ulcer, severe patient can be with bleeding or perforation.Therefore, in order to improve its bioavilability, the times for spraying and pair for reducing patient are anti- Should, improve its compliance, research brufen sustained-release preparation turn into clinical treatment in the urgent need to.
At present, brufen sustained-release preparation is mainly matrix type, the hydrophilic gel being prepared into using high-molecular organic material Type or microsphere sustained-release preparation, however, some high-molecular organic materials when as drug delivery system there is also some defects, such as Mechanical strength is low, poor chemical stability, biocompatibility are undesirable, or even has certain toxicity, limits it in vivo Application.
In contrast to this, the silica (SiO of ordered mesoporous material such as nanostructured2) as drug carrier material there is nothing Poison, preferably biocompatibility, chemistry and mechanical stability, hydrophilic and porous etc. property, can control adsorbed or wrap in theory The diffusion rate of medicine is buried, and is not swelled under pH value change, does not also change porous, is also less prone to by microorganism attack, So causing the extensive concern of people.Meanwhile, single SiO2Material is difficult to as drug controlled release system there are still some The difficulty of solution.First, earth silicon material drug loading is relatively low, can significantly improve production cost;Second, silica material Expect that rate of release is very fast after carrying medicament, is unable to reach sustained release purpose sometimes;3rd, earth silicon material is mainly in this area Simple carrying medicament, can cause medicine stability to reduce on the premise of without any auxiliary material.
The content of the invention
The first aspect of the present invention is to provide a kind of preparation method of ibuprofen sustained release capsules, and it comprises the following steps:
1) mesoporous material and polyethylene glycol are added and ultrasound is carried out in solvent;
2) brufen is added into dicyandiamide solution, stirring solvent flashing obtains the mesoporous particles of load brufen;
3) mesoporous particles are coated using organic polymer auxiliary material, the particle of acquisition pulverizes and sieves, encapsulated to produce.
In one embodiment, the mesoporous material is selected from mesoporous silica particles and open-cell polypropylene particle foams One or both of.
In still another embodiment, the mesoporous silica particles are selected from MCM-41, SBA-15, HMS, MSU, SBA- 3rd, the one or more in MCM-48 and TUD-1;Preferably SBA-15, the SBA-15 particle diameter are 1-2 μm, and average pore size is 8-11nm, specific surface area 600m2/g。
In another embodiment, the particle diameter of the open-cell polypropylene particle foams is 250-350 μm, and average pore size is 5-20 μm, percent opening is 70%.
In a preferred embodiment, the one kind or many of the solvent in methanol, ethanol, acetone and dichloromethane Kind.
In still another embodiment, the weight ratio of the brufen, mesoporous material and polyethylene glycol is 1:0.5-5: 0.1-0.5.Further, the mesoporous material is made up of mesoporous silica particles and polypropylene porous particle, described mesoporous The weight ratio of silica dioxide granule and polypropylene porous particle is 1:0.2-2;Further, the brufen, mesoporous dioxy The weight ratio of silicon carbide particle, open-cell polypropylene particle foams and polyethylene glycol is 1:0.5:0.4:0.3.
It is preferably carried out at one in scheme, in step 1) in, methyl hexadecanoate, the cloth are also added into the solvent The weight ratio of ibuprofen and methyl hexadecanoate is 1:0.05.
In another embodiment, the organic polymer auxiliary material is hydroxypropyl methylcellulose, methylcellulose, ethyl fibre Tie up element, acrylic resin I-IV, hydroxypropyl cellulose, hypromellose phthalate, phthalic acid acetic acid fibre One or more in dimension element and styrol maleic acid copolymers.
In one specifically embodiment, the preparation method of the ibuprofen sustained release capsules is as follows:
1) by SBA-15 and polyethylene glycol by weight 0.5:0.2 adds ultrasound 10-15min in ethanol;
2) brufen is added into dicyandiamide solution, wherein, brufen and SBA-15 weight ratio are 1:1, stirring volatilization is molten Agent obtains the SBA-15 particles of load brufen;
3) hypromellose phthalate is dissolved in methanol-acetone solution (volume ratio 1:1) in, then to solution The middle SBA-15 particles for adding load brufen, SBA-15 particles and the hydroxypropyl methylcellulose O-phthalic of the load brufen The weight ratio of acid esters is 2:1, solvent flashing is stirred, the particle of acquisition crushes sieving for standby;
4) by open-cell polypropylene particle foams and polyethylene glycol by weight 0.4:0.1 adds ultrasound 15- in ethanol 20min;
5) brufen is added into dicyandiamide solution, wherein, the weight ratio of brufen and open-cell polypropylene particle foams is 0.5:0.4, stirring solvent flashing obtains the open-cell polypropylene particle foams of load brufen;
6) IV acrylic resins are dissolved in ethanol, the perforate polypropylene bubble of load brufen is then added into solution Foam particle, the open-cell polypropylene particle foams of the load brufen are 3 with the weight ratio of IV acrylic resins:1, stirring is waved Solvent is sent out, the particle of acquisition pulverizes and sieves, the particle obtained with step 3 loads capsule after being well mixed and produced.
The second aspect of the present invention is to provide ibuprofen sustained release capsules prepared by a kind of above method.
The third aspect of the present invention is to provide the ibuprofen sustained release capsules in terms for the treatment of inflammation or pain disease is prepared Application in medicine.
Present invention discover that during mesoporous material load brufen, can after addition polyethylene glycol and methyl hexadecanoate To improve load capacity of the mesoporous material to brufen, and on the premise of high capacity amount, it can also be ensured that load brufen is situated between The sustained release rate of Porous materials and the stability of preparation.In addition, the spansule prepared by the present invention, auxiliary without adding other Material, preparation process is simple, and two kinds of different mesoporous particles are absorbed by the body in stomach and small intestine respectively, hence it is evident that improves brufen and delays Release the bioavilability of capsule.
Embodiment
Also the present invention further can be understood by embodiment, wherein the embodiment illustrates that some are prepared or user Method.It is to be appreciated, however, that these embodiments do not limit the present invention.The change of the invention of currently known or further exploitation Change is considered within the scope of the invention described herein and claimed below.
In following examples, used SBA-15 particle diameter is 1-2 μm, and average pore size is 8-11nm, specific surface area 600m2/g.The particle diameter of used open-cell polypropylene particle foams is 250-350 μm, and average pore size is 5-20 μm, and percent opening is 70%.
The preparation of the ibuprofen sustained release capsules of embodiment 1
1) prepared by the silica slow-releasing granules of load brufen
0.5g SBA-15 (Shanghai Zhen Zhun bio tech ltd) and 0.2g polyethylene glycol 400s are added into 50ml ethanol Middle ultrasonic 10-15min;Then 0.5g brufens are added into dicyandiamide solution, rotary evaporation of solvent after 4h is stirred at room temperature and is obtained Load the SBA-15 particles of brufen;0.5g hypromellose phthalates are dissolved in 50ml methanol-acetone solution (bodies Product compares 1:1) in, then added into solution after the SBA-15 particles that 1g loads brufen, stirring 1h, rotary evaporation of solvent is obtained It is standby that the particle obtained crushed 40 mesh sieves;
2) prepared by the perforate polypropylene foam slow-releasing granules of load brufen
By 0.4g open-cell polypropylene particle foams (being purchased from Shanghai Jun Sheng bio tech ltd) and 0.1g polyethylene glycol 400 add ultrasound 15-20min in 50ml ethanol;0.5g brufens are added into dicyandiamide solution, solvent is evaporated under reduced pressure after stirring and obtains The open-cell polypropylene particle foams of brufen must be loaded;0.3g IV acrylic resins are dissolved in 30ml ethanol, Ran Houxiang The open-cell polypropylene particle foams of 0.9g load brufen are added in solution, 30min is stirred, solvent is evaporated under reduced pressure, acquisition Particle crushed 40 mesh sieves, was produced with loading loading capsule after the silica dioxide granule of brufen is well mixed.
The preparation of the ibuprofen sustained release capsules of embodiment 2
1) prepared by the silica slow-releasing granules of load brufen
By 0.5g SBA-15 (Shanghai Zhen Zhun bio tech ltd), 0.2g polyethylene glycol 400s and 30mg palmitic acid first Ester adds ultrasound 10-15min in 50ml ethanol;Then 0.5g brufens are added into dicyandiamide solution, stirs revolved after 4h at room temperature Turn the SBA-15 particles that evaporation solvent obtains load brufen;0.5g hypromellose phthalates are dissolved in 50ml first Alcohol-acetone soln (volume ratio 1:1) in, then added into solution after the SBA-15 particles that 1g loads brufen, stirring 1h, rotation Turn evaporation solvent, it is standby that the particle of acquisition crushed 40 mesh sieves;
2) prepared by the perforate polypropylene foam slow-releasing granules of load brufen
0.4g open-cell polypropylene particle foams, 0.1g polyethylene glycol 400s and 20mg methyl hexadecanoates are added into 50ml ethanol Middle ultrasonic 15-20min;0.5g brufens are added into dicyandiamide solution, solvent is evaporated under reduced pressure after stirring and obtains load brufen Open-cell polypropylene particle foams;0.3g IV acrylic resins are dissolved in 30ml ethanol, 0.9g is then added into solution Load brufen open-cell polypropylene particle foams, stir 30min, solvent be evaporated under reduced pressure, the particle of acquisition crushed 40 mesh Sieve, is produced with loading loading capsule after the silica dioxide granule of brufen is well mixed.
In Examples 1 and 2, the perforate polypropylene foam slow-releasing granules finished product density of the load brufen of preparation is in 0.7- 0.9g/cm3;Therefore it can be suspended in human gastric juice, so as to reach the purpose that stomach sustained release absorbs.
The mesoporous material brufen load capacity of embodiment 3 is investigated
20mg mesoporous materials and the polyethylene glycol and methyl hexadecanoate of various dose are taken as ultrasonic in 50ml ethanol 15min, then adds 20mg (SBA-15) and 30mg (perforate polypropylene foam) brufen respectively, and purple is passed through after stirring 6h Determination of ibuprofen in outer spectrophotometry ethanol solution, calculates drug loading and envelop rate;Envelop rate=(add cloth Lip river Fragrant weight-ethanol solution brufen weight)/add brufen weight;Drug loading=(add brufen weight-ethanol molten Liquid brufen weight)/(adding brufen weight-ethanol solution brufen weight+mesoporous material weight);Concrete outcome is as follows:
SBA-15 Polyethylene glycol Methyl hexadecanoate Envelop rate Load capacity
Group 1 - - 50.9% 33.7%
Group 2 8mg - 78.3% 43.9%
Group 3 8mg 1.2mg 91.6% 47.8%
Group 4 12mg - 72.4% 41.9%
Group 5 12mg 2mg 72.9% 42.2%
Polypropylene foam Polyethylene glycol Methyl hexadecanoate Envelop rate Load capacity
Group 1 - - 67.5% 48.9%
Group 2 5mg - 83.9% 55.7%
Group 3 5mg 0.8mg 90.4% 57.5%
Group 4 10mg - 80.2% 54.5%
Group 5 10mg 1.2mg 81.3% 54.9%
The release in vitro research of the ibuprofen sustained release capsules of embodiment 4
Ibuprofen sustained release capsules prepared by Examples 1 and 2, take two kinds of slow-releasing granules according to States Pharmacopoeia specifications, survey respectively respectively Determine its release in simulated gastric fluid and simulated intestinal fluid, concrete outcome is as follows:
1) accumulative releasing degree in simulated gastric fluid
2) accumulative releasing degree in simulated intestinal fluid
Type 2h 4h 8h 16h 24h
Embodiment 1 SBA‐15 6.1% 14.2% 29.1% 60.3% 91.4%
Embodiment 2 SBA‐15 6.6% 15.9% 33.7% 64.8% 95.5%
Comparative example 1 SBA‐15 9.2% 42.6% 91.4% 93.5% 97.1%
Comparative example 1 is the preparation method according to embodiment 2, without polyethylene glycol and palm first in mesoporous material loading process Ester, other consumptions and proportioning be the same as Example 2
The vivo biodistribution availability research of the ibuprofen sustained release capsules of embodiment 5
Male SD rat, body weight 200g or so are taken, gavage gives cloth prepared by brufen bulk drug, Examples 1 and 2 respectively Ibuprofen sustained release capsules content prepared by ibuprofen spansule content and comparative example, each group dosage is equal in terms of brufen For 25mg/kg, carry out eye socket with 30min, 1h, 2h, 4h, 8h, 16h and 24h respectively and take blood, using HPLC methods to each time point Determination of ibuprofen is detected in blood sample, calculates blood concentration, and by DAS2.0 softwares, in terms of brufen bulk drug, is calculated The relative bioavailability of each group preparation, concrete outcome is as follows:
AUC(0-24h) Relative bioavailability
Brufen raw material 26.1±17.9mg/L*h -
Embodiment 1 137.4±72.4mg/L*h 526%
Embodiment 2 159.2±89.8mg/L*h 610%
Comparative example 1 113.5±61.6mg/L*h 435%
Comparative example 2 89.8±43.9mg/L*h 344%
The be the same as Example 4 of comparative example 1
Comparative example 2 is only comprising the SBA-15 slow-releasing granules for loading brufen in comparative example 1
The study on the stability of the ibuprofen sustained release capsules of embodiment 6
According to Chinese Pharmacopoeia two annex bulk drugs of version in 2010 and pharmaceutical preparation stability test guideline, in high temperature (temperature is 45 DEG C ± 2 DEG C, and relative humidity is 75% ± 5%RH) carries out stability test (12 months) under super-humid conditions, passes through Active component content in ibuprofen sustained release capsules made from HPLC detection methods measure Examples 1 and 2,0 month after being saved, The percentage of 3 months, 6 months and the determination of ibuprofen after 12 months relative to labelled amount.
Present invention merely illustrates some claimed specific embodiments, one of them or more skill Described technical characteristic can be combined with arbitrary one or more technical schemes in art scheme, and these are combined and obtain Technical scheme also in the application protection domain, technical scheme is disclosed in the present invention just as obtained from these are combined It is specific in content to record the same.

Claims (10)

1. a kind of preparation method of ibuprofen sustained release capsules, it comprises the following steps:
1) mesoporous material and polyethylene glycol are added and ultrasound is carried out in solvent;
2) brufen is added into dicyandiamide solution, stirring solvent flashing obtains the mesoporous particles of load brufen;
3) mesoporous particles are coated using organic polymer auxiliary material, the particle of acquisition pulverizes and sieves, encapsulated to produce.
2. preparation method according to claim 1, it is characterised in that the mesoporous material is selected from mesoporous silica particles One or both of with open-cell polypropylene particle foams.
3. preparation method according to claim 2, it is characterised in that the mesoporous silica particles be selected from MCM-41, One or more in SBA-15, HMS, MSU, SBA-3, MCM-48 and TUD-1;Preferably SBA-15, the grain of the SBA-15 Footpath is 1-2 μm, and average pore size is 8-11nm, specific surface area 600m2/g.The particle diameter of the open-cell polypropylene particle foams is 250- 350 μm, average pore size is 5-20 μm, and percent opening is 70%.
4. preparation method according to claim 1, it is characterised in that the brufen, mesoporous material and polyethylene glycol Weight ratio is 1:0.5-5:0.1-0.5.Further, the mesoporous material is by porous of mesoporous silica particles and polypropylene Grain composition, the weight ratio of mesoporous silica particles and the polypropylene porous particle is 1:0.2-2;Further, it is described Brufen, mesoporous silica particles, the weight ratio of open-cell polypropylene particle foams and polyethylene glycol are 1:0.5:0.4:0.3.
5. preparation method according to claim 1, it is characterised in that the solvent is selected from methanol, ethanol, acetone and dichloro One or more in methane.
6. preparation method according to claim 1, it is characterised in that in step 1) in, palm fibre is also added into the solvent Palmitic acid acid methyl esters, the weight ratio of the brufen and methyl hexadecanoate is 1:0.05.
7. preparation method according to claim 1, it is characterised in that the organic polymer auxiliary material is hypromellose Element, methylcellulose, ethyl cellulose, acrylic resin I-IV, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalic acid One or more in ester, cellulose acetate-phthalate and styrol maleic acid copolymers.
8. the preparation method according to claim any one of 1-7, it is characterised in that the preparation of the ibuprofen sustained release capsules Method is as follows:
1) by SBA-15 and polyethylene glycol by weight 0.5:0.2 adds ultrasound 10-15min in ethanol;
2) brufen is added into dicyandiamide solution, wherein, brufen and SBA-15 weight ratio are 1:1, stirring solvent flashing is obtained The SBA-15 particles of brufen must be loaded;
3) hypromellose phthalate is dissolved in methanol-acetone solution (volume ratio 1:1) in, then add into solution Enter to load the SBA-15 particles of brufen, the SBA-15 particles and hypromellose phthalate of the load brufen Weight ratio be 2:1, solvent flashing is stirred, the particle of acquisition crushes sieving for standby;
4) by open-cell polypropylene particle foams and polyethylene glycol by weight 0.4:0.1 adds ultrasound 15-20min in ethanol;
5) brufen is added into dicyandiamide solution, wherein, the weight ratio of brufen and open-cell polypropylene particle foams is 0.5: 0.4, stirring solvent flashing obtains the open-cell polypropylene particle foams of load brufen;
6) IV acrylic resins are dissolved in ethanol, the perforate polypropylene foam of load brufen is then added into solution Grain, the open-cell polypropylene particle foams of the load brufen and the weight ratio of IV acrylic resins are 3:1, stirring volatilization is molten Agent, the particle of acquisition pulverizes and sieves, and the particle obtained with step 3 loads capsule after being well mixed and produced.
9. ibuprofen sustained release capsules prepared by a kind of any one of claim 1-8 preparation methods.
10. application of the ibuprofen sustained release capsules described in claim 9 in medicine in terms of preparing treatment inflammation or pain disease.
CN201710403211.3A 2017-06-01 2017-06-01 A kind of preparation method of ibuprofen sustained release capsules Active CN107184565B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710403211.3A CN107184565B (en) 2017-06-01 2017-06-01 A kind of preparation method of ibuprofen sustained release capsules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710403211.3A CN107184565B (en) 2017-06-01 2017-06-01 A kind of preparation method of ibuprofen sustained release capsules

Publications (2)

Publication Number Publication Date
CN107184565A true CN107184565A (en) 2017-09-22
CN107184565B CN107184565B (en) 2018-04-03

Family

ID=59876343

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710403211.3A Active CN107184565B (en) 2017-06-01 2017-06-01 A kind of preparation method of ibuprofen sustained release capsules

Country Status (1)

Country Link
CN (1) CN107184565B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108992706A (en) * 2018-08-08 2018-12-14 上海应用技术大学 A kind of antibiotic continues acrylic resin bone cement efficiently discharged and preparation method thereof
CN109966268A (en) * 2019-04-04 2019-07-05 吉林市吴太感康药业有限公司 A kind of preparation method of ibuprofen sustained release capsules
CN113768899A (en) * 2021-09-29 2021-12-10 广东彼迪药业有限公司 Colloidal bismuth pectin capsule and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1530138A (en) * 2003-03-13 2004-09-22 �����ɷ� Stabilized medicine preparation form with by porous kietyoite covering flavour
CN101909601A (en) * 2008-01-18 2010-12-08 陶氏环球技术公司 Use methoxy poly (ethylene glycol) to strengthen the method for the water solubility of hardly soluble active substances
CN102448448A (en) * 2009-05-29 2012-05-09 弗拉梅技术公司 Controlled-release floating pharmaceutical compositions
CN103099789A (en) * 2013-02-21 2013-05-15 河北维尔康制药有限公司 Preparation method of vitamin C granules
CN103565765A (en) * 2012-07-30 2014-02-12 南京亿华药业有限公司 Preparation of ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug
CN104415340A (en) * 2013-08-23 2015-03-18 中国科学院大连化学物理研究所 Solid drug preparation and preparing method thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1530138A (en) * 2003-03-13 2004-09-22 �����ɷ� Stabilized medicine preparation form with by porous kietyoite covering flavour
CN101909601A (en) * 2008-01-18 2010-12-08 陶氏环球技术公司 Use methoxy poly (ethylene glycol) to strengthen the method for the water solubility of hardly soluble active substances
CN102448448A (en) * 2009-05-29 2012-05-09 弗拉梅技术公司 Controlled-release floating pharmaceutical compositions
CN103565765A (en) * 2012-07-30 2014-02-12 南京亿华药业有限公司 Preparation of ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug
CN103099789A (en) * 2013-02-21 2013-05-15 河北维尔康制药有限公司 Preparation method of vitamin C granules
CN104415340A (en) * 2013-08-23 2015-03-18 中国科学院大连化学物理研究所 Solid drug preparation and preparing method thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
SW SONG等人: ""Functionalized SBA-15 Materials as Carriers for Controlled Drug Delivery:Influence of Surface Properties on Matrix-Drug Interactions"", 《LANGMUIR THE ACS JOURNAL OF SURFACES & COLLOIDS》 *
WUJUN XU等人: ""pH-Controlled drug release from mesoporous silica tablets coated with hydroxypropyl methylcellulose phthalate"", 《MATERIALS RESEARCH BULLETIN》 *
倪敏等人: ""布洛芬/SBA-15 纳米缓控释药物的超临界制备及其释放特性研究"", 《第九届全国超临界流体技术学术及应用研讨会论文集》 *
徐武军: ""基于HPMCP包覆介孔SBA-15的pH敏感药物缓释系统"", 《化学学报》 *
赵飞船: ""布洛芬在中孔分子筛上的负载与缓释研究"", 《中国知网系列数据库(CNKI)》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108992706A (en) * 2018-08-08 2018-12-14 上海应用技术大学 A kind of antibiotic continues acrylic resin bone cement efficiently discharged and preparation method thereof
CN109966268A (en) * 2019-04-04 2019-07-05 吉林市吴太感康药业有限公司 A kind of preparation method of ibuprofen sustained release capsules
CN113768899A (en) * 2021-09-29 2021-12-10 广东彼迪药业有限公司 Colloidal bismuth pectin capsule and preparation method thereof

Also Published As

Publication number Publication date
CN107184565B (en) 2018-04-03

Similar Documents

Publication Publication Date Title
CN101583620B (en) Ganaxolone formulations and preparation and application thereof
JP4969104B2 (en) Porous cellulose aggregate and molded body composition thereof
CN107184565B (en) A kind of preparation method of ibuprofen sustained release capsules
JPWO2006115198A1 (en) Porous cellulose aggregate and molded body composition thereof
JPS629A (en) Sustained release compound unit pharmaceutical
CN103550158B (en) Emodin solid dispersion, drug-containing pellet core, colonic targeted micropill, and applications of three
CN106983734B (en) A kind of ibuprofen sustained release capsules and preparation method thereof
CN103784396B (en) Ibuprofen oral micropill xerogel and preparation method thereof
Nguyen et al. Rapid Indomethacin Release from Porous Pectin Particles as a Colon-Targeted Drug Delivery System
CN113842370B (en) Abidol hydrochloride tablet and preparation method thereof
CN104814923B (en) A kind of tamsulosin hydrochloride sustained release preparation and preparation method thereof and its application
CN1771913B (en) Emulifying solvent diffusing process for preparing taste masked micro ball
Mehta et al. Solvent evaporation technique: An innovative approach to increase gastric retention
Zhang et al. Development of protocatechualdehyde proliposomes-based sustained-release pellets with improved bioavailability and desired pharmacokinetic behavior for angina chronotherapy
CN103860464B (en) A kind of Claritin slow-release suspension and preparation method thereof
CN108042495B (en) A kind of Glipizide lipid nano particle solid pharmaceutical preparation
CN100562322C (en) Colon targeting preparation of a kind of 5-aminosalicylic acid and preparation method thereof
CN105732517A (en) Medicine preparation containing 5-fluorouracil drug eutectic with nicotinamide as precursor and preparation method of medicine preparation
Kouchak et al. Preparation and in vitro evaluation of a microballoon delivery system for theophylline
Gupta et al. Fabrication and evaluation of fluvastatin sodium loaded sustained release microspheres using polymer blends
CN104288107B (en) Sustained-release floating micropill, pharmaceutical composition containing the pellet and preparation method thereof
CN102631324A (en) Nimesulide self-emulsification particle and preparation method thereof
CN101647782A (en) Vinpocetine oral administration self-microemulsifying pellet as well as preparation method and application thereof
Patil MICROBEADS BY IONOTROPIC GELATION TECHNIQUE
CN102961354A (en) Acemetacin three-layer controlled release tablet and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant